Insights

Recent Funding Boost AsclepiX Therapeutics secured $10M in Series A-3 funding on Jul 14th '23, reflecting investor confidence in the company's innovative approach to developing peptides for retinal diseases.

Executive Team Strengthening The recent appointments of key executives, including Amir Shojaei as Chief Scientific Officer and Robert J. Dempsey as CEO, indicate strategic leadership enhancements which could lead to new collaborations and business opportunities.

Technology Utilization Utilizing a tech stack that includes Shopify, Twitter Emoji, and Google Font API, AsclepiX Therapeutics demonstrates a commitment to cutting-edge technologies, signaling potential synergies with technology-focused clients or partners.

Market Recognition AsclepiX has garnered significant market attention, evident from raising $35M in Series A funding on Jan 1st '20 and being highlighted in top deals for biotech funding rounds. This recognition might open doors for strategic collaborations and expansion opportunities.

Clinical Expertise With the appointment of Theresa G. H. Heah as Chief Medical Officer, AsclepiX showcases its commitment to medical excellence. This expertise can be leveraged to explore partnerships with healthcare institutions and professionals for clinical trials and treatments.

AsclepiX Therapeutics, Inc. Tech Stack

AsclepiX Therapeutics, Inc. uses 8 technology products and services including Shopify, Font Awesome, Twitter Emoji (Twemoji), and more. Explore AsclepiX Therapeutics, Inc.'s tech stack below.

  • Shopify
    E-commerce
  • Font Awesome
    Font Scripts
  • Twitter Emoji (Twemoji)
    Font Scripts
  • Google Font API
    Font Scripts
  • Modernizr
    Javascript Libraries
  • SiteGround
    Platform As A Service
  • PHP
    Programming Languages
  • Nginx
    Web Servers

Media & News

AsclepiX Therapeutics, Inc.'s Email Address Formats

AsclepiX Therapeutics, Inc. uses at least 1 format(s):
AsclepiX Therapeutics, Inc. Email FormatsExamplePercentage
FLast@asclepix.comJDoe@asclepix.com
45%
LastFirst@asclepix.comDoeJohn@asclepix.com
5%
FLast@asclepix.comJDoe@asclepix.com
45%
LastFirst@asclepix.comDoeJohn@asclepix.com
5%

Frequently Asked Questions

Where is AsclepiX Therapeutics, Inc.'s headquarters located?

Minus sign iconPlus sign icon
AsclepiX Therapeutics, Inc.'s main headquarters is located at 301 West 29th Street Suite 2004 Baltimore, Maryland 21211 US. The company has employees across 2 continents, including North AmericaAsia.

What is AsclepiX Therapeutics, Inc.'s official website and social media links?

Minus sign iconPlus sign icon
AsclepiX Therapeutics, Inc.'s official website is asclepix.com and has social profiles on LinkedIn.

How much revenue does AsclepiX Therapeutics, Inc. generate?

Minus sign iconPlus sign icon
As of July 2025, AsclepiX Therapeutics, Inc.'s annual revenue reached $750K.

What is AsclepiX Therapeutics, Inc.'s SIC code NAICS code?

Minus sign iconPlus sign icon
AsclepiX Therapeutics, Inc.'s SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does AsclepiX Therapeutics, Inc. have currently?

Minus sign iconPlus sign icon
As of July 2025, AsclepiX Therapeutics, Inc. has approximately 7 employees across 2 continents, including North AmericaAsia. Key team members include Chief Executive Officer, President: R. D.Chief Scientific Officer, Evp-Clinical Development: A. S.Vice President Finance: J. V. T.. Explore AsclepiX Therapeutics, Inc.'s employee directory with LeadIQ.

What industry does AsclepiX Therapeutics, Inc. belong to?

Minus sign iconPlus sign icon
AsclepiX Therapeutics, Inc. operates in the Biotechnology Research industry.

What technology does AsclepiX Therapeutics, Inc. use?

Minus sign iconPlus sign icon
AsclepiX Therapeutics, Inc.'s tech stack includes ShopifyFont AwesomeTwitter Emoji (Twemoji)Google Font APIModernizrSiteGroundPHPNginx.

What is AsclepiX Therapeutics, Inc.'s email format?

Minus sign iconPlus sign icon
AsclepiX Therapeutics, Inc.'s email format typically follows the pattern of . Find more AsclepiX Therapeutics, Inc. email formats with LeadIQ.

How much funding has AsclepiX Therapeutics, Inc. raised to date?

Minus sign iconPlus sign icon
As of July 2025, AsclepiX Therapeutics, Inc. has raised $10M in funding. The last funding round occurred on Jul 26, 2023 for $10M.
AsclepiX Therapeutics, Inc.

AsclepiX Therapeutics, Inc.

Biotechnology ResearchMaryland, United States2-10 Employees

FRAUD ALERT: AsclepiX is aware of individuals representing job postings that are not legitimate positions. AsclepiX is NOT hiring at this time. 

AsclepiX Therapeutics is a clinical-stage biopharmaceutical company leveraging computational biology from Johns Hopkins to identify and develop peptides for improved treatments of retinal diseases. Our lead candidate, AXT107, inhibits pro-angiogenic vascular endothelial growth factor receptor 2 (VEGFR2) and activates the vessel stabilizing receptor tyrosine kinase (Tie2), the two validated pathways for the treatment of retinal vascular diseases.

Section iconCompany Overview

Headquarters
301 West 29th Street Suite 2004 Baltimore, Maryland 21211 US
SIC Code
8733 - Noncommercial Research Organizations
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Employees
2-10

Section iconFunding & Financials

  • $10M

    AsclepiX Therapeutics, Inc. has raised a total of $10M of funding over 3 rounds. Their latest funding round was raised on Jul 26, 2023 in the amount of $10M.

  • $10M

    AsclepiX Therapeutics, Inc.'s revenue is in the range of $10M

Section iconFunding & Financials

  • $10M

    AsclepiX Therapeutics, Inc. has raised a total of $10M of funding over 3 rounds. Their latest funding round was raised on Jul 26, 2023 in the amount of $10M.

  • $10M

    AsclepiX Therapeutics, Inc.'s revenue is in the range of $10M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.